IN-VITRO ACTIVITY OF LY333328 AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI, METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS, AND PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE

We report the activity of LY333328 against 35 clinical isolates of van comycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical i solates of methicillin-resistant S. aureus, and 29 clinical isolates o f high-level penicillin-resistant S. pneumoniae. All isolates of vanco mycin-resistant enterococci were inhibited by 2 mu g/mL LY333328, and 8 mu g/mL LY333328 suns bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 mu g/m L LY333328, and 4 mu g/mL LY333328 was bactericidal against all methic illin-resistant S. aureus isolates tested. All isolates of penicillin- resistant S. pneumoniae were inhibited by (0.125 mu g/mL LY333328, and 0.25 mu g/mL LY333328 was bactericidal against all S. pneumoniae isol ates tested. LY333328 is a promising new glycopeptide antimicrobial ag ent. (C) 1998 Elsevier Science Inc.